pCW57.1-FOXM1c Citations (9)
Originally described in: Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR Oncotarget. 2015 Jul 16. PubMed Journal
Articles Citing pCW57.1-FOXM1c
| Articles |
|---|
Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer.
Barger CJ, Branick C, Chee L, Karpf AR.
Cancers (Basel). 2019 Feb 21;11(2). pii: cancers11020251. doi: 10.3390/cancers11020251.
PubMed
Associated Plasmids |
| NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma. Haque M, Li J, Huang YH, Almowaled M, Barger CJ, Karpf AR, Wang P, Chen W, Turner SD, Lai R. Cancers (Basel). 2019 Aug 6;11(8). pii: cancers11081119. doi: 10.3390/cancers11081119. PubMed |
| The transcription factor FOXM1 regulates the balance between proliferation and aberrant differentiation in head and neck squamous cell carcinoma. Roh V, Hiou-Feige A, Misetic V, Rivals JP, Sponarova J, Teh MT, Ferreira Lopes S, Truan Z, Mermod M, Monnier Y, Hess J, Tolstonog GV, Simon C. J Pathol. 2020 Jan;250(1):107-119. doi: 10.1002/path.5342. Epub 2019 Dec 3. PubMed |
| Metabolic Imaging Detects Resistance to PI3Kalpha Inhibition Mediated by Persistent FOXM1 Expression in ER(+) Breast Cancer. Ros S, Wright AJ, D'Santos P, Hu DE, Hesketh RL, Lubling Y, Georgopoulou D, Lerda G, Couturier DL, Razavi P, Pelossof R, Batra AS, Mannion E, Lewis DY, Martin A, Baird RD, Oliveira M, de Boo LW, Linn SC, Scaltriti M, Rueda OM, Bruna A, Caldas C, Brindle KM. Cancer Cell. 2020 Oct 12;38(4):516-533.e9. doi: 10.1016/j.ccell.2020.08.016. Epub 2020 Sep 24. PubMed |
| FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. Wang L, Shi C, Yu J, Xu Y. Cancer Cell Int. 2022 Jan 29;22(1):47. doi: 10.1186/s12935-021-02372-2. PubMed |
| Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Doepner M, Lee I, Natale CA, Brathwaite R, Venkat S, Kim SH, Wei Y, Vakoc CR, Capell BC, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME, Ridky TW. Sci Adv. 2022 Sep 2;8(35):eabn4007. doi: 10.1126/sciadv.abn4007. Epub 2022 Sep 2. PubMed |
| Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. Nandi I, Smith HW, Sanguin-Gendreau V, Ji L, Pacis A, Papavasiliou V, Zuo D, Nam S, Attalla SS, Kim SH, Lusson S, Kuasne H, Fortier AM, Savage P, Martinez Ramirez C, Park M, Katzenellenbogen JA, Katzenellenbogen BS, Muller WJ. J Clin Invest. 2023 Apr 3;133(7):e162324. doi: 10.1172/JCI162324. PubMed |
| FOXM1 is critical for the fitness recovery of chromosomally unstable cells. Pan F, Chocarro S, Ramos M, Chen Y, Alonso de la Vega A, Somogyi K, Sotillo R. Cell Death Dis. 2023 Jul 14;14(7):430. doi: 10.1038/s41419-023-05946-2. PubMed |
| CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34. Huang Z, Kaller M, Hermeking H. Cell Death Differ. 2023 Aug;30(8):2017-2034. doi: 10.1038/s41418-023-01193-2. Epub 2023 Jul 24. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.